5402-60-8

Basic information

• Product Name: 2,6-Dimethylbenzyl chloride
• Synonyms: 1-CHLOROMETHYL-2,6-DIMETHYLBENZENE;2-CHLOROMETHYL-1,3-DIMETHYL-BENZENE;2,6-DIMETHYLBENZYL CHLORIDE;2-(Chloromethyl)-1,3-dimethylbenzene, 2-(Chloromethyl)-m-xylene;[(2,6-diMethylphenyl)Methyl]chloranuide
• CAS NO: 5402-60-8
• Molecular Formula: C₉H₁₁Cl
• Molecular Weight: 154.64
• Product Categories: Benzene derivatives
• Mol File: 5402-60-8.mol

Chemical Properties

• Melting Point: 33-35°C
• Boiling Point: 70°C 5mm
• Flash Point: 33 °C
• Appearance: /
• Density: 1.033 g/cm³
• Vapor Pressure: 0.132mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,6-Dimethylbenzyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dimethylbenzyl chloride(5402-60-8)
• EPA Substance Registry System: 2,6-Dimethylbenzyl chloride(5402-60-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• HazardClass: IRRITANT, LACHRYMATOR
• Hazardous Substances Data: 5402-60-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dimethylbenzyl chloride is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a building block in the development of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dimethylbenzyl chloride is utilized as a precursor in the production of insecticides. Its chemical properties make it suitable for creating effective compounds that help protect crops from pests and enhance agricultural productivity.
Used in Dye Industry:
2,6-Dimethylbenzyl chloride is employed as a crucial intermediate in the manufacturing of dyes. Its versatility in chemical reactions enables the creation of a wide range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Disinfectant Production:
This chemical compound is also used as a building block in the synthesis of disinfectants. Its ability to form stable compounds with biocidal properties makes it valuable in the development of products that help maintain cleanliness and prevent the spread of diseases.
Safety Considerations:
Due to its degree of toxicity, 2,6-Dimethylbenzyl chloride should be handled with caution. It is essential to work in a well-ventilated environment and follow proper safety protocols to minimize health risks associated with its use in various industrial processes.

InChI:InChI=1/C9H11Cl/c1-7-4-3-5-8(2)9(7)6-10/h3-5H,6H2,1-2H3

Upstream product

• 7093-91-6 chloromethyl isocyanate 
• 108-38-3 m-xylene 
• 87-62-7 2,6-dimethylaniline 
• 608-28-6 2,6-dimethyliodobenzene 
• 632-46-2 2,6-dimethylbenzoic acid 
• 1123-56-4 2,6-dimethylbenzaldehyde 
• 50-00-0 formaldehyd 
• 62285-58-9 2,6-dimethylbenzyl alcohol 

Downstream Products

• 902526-55-0 Diaethyl-2,6-dimethylbenzylphosphonat 
• 54708-14-4 2,6-dimethylphenylacetonitrile 
• 540524-67-2 (2,6-dimethylphenyl)methanesulfonyl chloride 
• 51739-98-1 2,6-dimethylbenzyl radical 
• 76574-64-6 6-(2,6-Dimethyl-phenyl)-pyrido[2,3-d]pyrimidin-7-ylamine 
• 76574-87-3 6-(2,6-Dimethyl-phenyl)-2-methyl-pyrido[2,3-d]pyrimidin-7-ylamine 
• 847142-01-2 4-[(2,6-dimethylbenzyl)-thio]acetophenone 
• 126328-93-6 2-Iodomethyl-1,3-dimethyl-benzene 
• 875769-60-1 (2,6-dichloro-3-nitropyridin-4-yl)-(2,6-dimethylbenzyl)amine 
• 101773-24-4 5-allyl-1,2,3-trimethylbenzene 
• 1050479-72-5 methyl 2-[1-(2,6-dimethylbenzyl)-1H-benzimidazol-2-yl]benzoate 
• 478163-34-7 3-(2,6-dimethylbenzyloxy)acetophenone 
• 403668-99-5 isopropyl 8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate 

Relevant articles and documents

PROCESS FOR PREPARING 2,6-DIALKYLPHENYLACETIC ACIDS

The invention relates to a multi-stage process for preparing 2,6-dialkylphenylacetic acids of the general formula (I) by reacting 2,6-dialkylbromobenzenes with (1) magnesium, (2) a formamide, (3) an acid, (4) hydrogenation of the benzaldehyde obtained, (5

BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME

The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS

The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

Synthesis and molecular structures of zirconium and hafnium complexes bearing dimethylsilandiyl-bis-2,4,6-trimethylindenyl and dimethylsilandiyl-bis- 2-methyl-4,6-diisopropylindenyl ligands

Zirconium and hafnium ansa-complexes containing 2,4,6-trialkyl-substituted indenyl fragments were synthesized and unambiguously characterized. Mixtures of rac- and meso-Me2Si(2-Me-4,6-R2C9H 3-η5)2MCl2, where R = Me, i-Pr and M = Zr, Hf, were obtained by a treatment of MCl4 by dilithium salts of the respective bis(2,4,6-trialkylindenyl)dimethylsilanes in toluene. Alternatively, better yields of the same complexes can be obtained by the reaction between metal tetrachlorides and indenyl-tin derivatives gave the desired ansa-metallocenes. All rac- and meso-complexes of Zr and Hf were isolated in an analytically pure form, and six of these ansa-metallocenes were characterized by X-ray crystal structure analysis.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0 or 1; q is 0 or 1; t is 0 or 1; R5 is alkyl having from 1 to 3 carbon atoms; R9 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and X is -CH2-, Q is -OR1and R1 is methyl or ethyl; or X is -CH2CR12R13- or - CH2CH(NHAc)-wherein each of R12 and R13is independently hydrogen or methyl, Q is OR1 and R1 is hydrogen or alkyl having from 1 to 7 carbon atoms; or X is -CH2CH2- and Q is NR10R1'wherein one of R10 and R11is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy- 4-phenylbutyric acid], with a hydroxymethylcarbonyl (HMC) isostere as the active moiety. A systematic evaluation of structure - activity relationships for HIV protease inhibition, anti-HIV activities, and pharmacokinetic profiles has led to the delineation of a set of structural characteristics that appear to afford an orally available HIV protease inhibitor. Optimum structures, exemplified by 21f (JE-2147), incorporated 3-hydroxy-2- methylbenzoyl groups as the P2 ligand, (R)-5,5-dimethyl-1,3-thiazolidine-4- carbonyl (Dmt) residue at the P1' site, and 2-methylbenzylcarboxamide group as the P2' ligand. The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals.

Synthesis of regioisomeric dimethylbenzyl mercapturic acids anticipated from the metabolism of 1,2,3-trimethylbenzene

The synthesis of two regioisomeric mercapturic acids, N-acetyl-S -(2,3-dimethylbenzyl)-L-cysteine and N-acetyl-S-(2,6-dimethylbenzyl)-L-cysteine, was undertaken to investigate the operation of mercapturic acid pathway in the metabolism of 1,2,3-trimethylbenzene. The method applied was based on that we described recently in the synthesis of mercapturic acids derived from m- and p-xylenes.

Ultrasound-Mediated Synthesis and Mass Spectrometric Fragmentation of Dimethyl-Substituted 1,2-Diphenylethanols, Convenient Dimethylstilbene Precursors

1,2-Diarylethanols were obtained in high yields by ultrasonic irradiation of mixtures of lithium sand, benzylic chlorides, and arenecarbaldehydes or aryl methyl ketones.The mass spectra of the alcohols contained dominant peaks for species formed by dehydration, α-cleavage processes and rearrangement involving hydrogen transfer.Acid-catalyzed dehydration of the alcohols gave the corresponding stilbenes in quantitative yields.

ARYLMETHYL ISOCYANATES

Chloromethyl isocyanate reacts readily with aromatic hydrocarbons in the presence of anhydrous ferric chloride or other catalysts of the Friedel-Crafts reaction with the formation of arylmethyl isocyanates.The latter add alcohols and amines readily, being converted into the corresponding substituted urethanes and ureas.When heated in the presence of catalytic amounts of 1,3-dimethylphosphol-3-ene they give substituted carbodiimides.

Antihypertensive Activity of 6-Arylpyridopyrimidin-7-amine Derivatives

A series of 51 6-arylpyridopyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat.A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyridopyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg.Normalized blood pressure levels could then be maintained by single daily oral doses.The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.